Indomethacin and Doxorubicin Resistance in Lung Cancer Cells
Author Information
Author(s): de Groot D J A, Timmer T, Spierings D C J, Le T K P, de Jong S, de Vries E G E
Primary Institution: University Medical Center Groningen
Hypothesis
Can indomethacin activate the death receptor-mediated apoptosis pathway to overcome doxorubicin resistance in small-cell lung cancer (SCLC) cells?
Conclusion
Indomethacin increases the cytotoxic activity of doxorubicin in a doxorubicin-resistant SCLC cell line partly via the death receptor apoptosis pathway, independent of Fas.
Supporting Evidence
- Indomethacin induced apoptosis in doxorubicin-resistant SCLC cells but not in sensitive cells.
- Indomethacin increased caspase activity and doxorubicin sensitivity in resistant cells.
- Fas-mediated apoptosis was functional in resistant cells only when a protein synthesis inhibitor was present.
Takeaway
This study shows that a drug called indomethacin can help make a type of cancer cell more sensitive to another drug, doxorubicin, by triggering a process that leads to cell death.
Methodology
The study used Western blotting and apoptosis assays to analyze the effects of indomethacin and doxorubicin on SCLC cell lines.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website